Although the inhibitory effect of SSG on Il-1β, Ifn-γ, and Cxcl10 was weaker than that of canakinumab, SSG more effectively promoted the release of anti-inflammatory factors compared to classic treatments of gout (Supplementary Figure S1A). Here, CXCL10 is linked to gout.